NASDAQ: FGENFibrogen Inc Stock
$7.15-0.20 (-2.72%)
Updated Jul 11, 2025
FGEN Price
$7.15
Fair Value Price
-$1.05
Market Cap
$28.90M
52 Week Low
$4.50
52 Week High
$38.25
P/E
-2.86x
P/B
-0.13x
P/S
-1.33x
PEG
N/A
Dividend Yield
N/A
Revenue
-$23.54M
Earnings
-$10.01M
Gross Margin
57.8%
Operating Margin
20.39%
Profit Margin
42.5%
Debt to Equity
-1.57
Operating Cash Flow
-$76M
Beta
1.42
Next Earnings
Aug 11, 2025
Ex-Dividend
N/A
Next Dividend
N/A
FGEN Overview
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine FGEN's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
FGEN
Ranked#176 of 475
Ranked#176 of 475
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.39 | A | |
| $8.80 | A | |
| $44.86 | A |
Be the first to know about important FGEN news, forecast changes, insider trades & much more!
FGEN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how FGEN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
FGEN ($7.15) is overvalued by 784% relative to our estimate of its Fair Value price of -$1.05 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
FGEN ($7.15) is not significantly undervalued (784%) relative to our estimate of its Fair Value price of -$1.05 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
FGEN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more FGEN due diligence checks available for Premium users.
Valuation
FGEN fair value
Fair Value of FGEN stock based on Discounted Cash Flow (DCF)
Price
$7.15
Fair Value
-$1.05
Undervalued by
784.00%
FGEN ($7.15) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
FGEN ($7.15) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
FGEN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
FGEN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.86x
Industry
-154.99x
Market
30.99x
FGEN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.13x
Industry
4.62x
FGEN's financial health
Profit margin
Revenue
$2.7M
Net Income
$4.6M
Profit Margin
169.4%
FGEN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
FGEN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$165.2M
Liabilities
$340.1M
Debt to equity
-1.57
FGEN's short-term assets ($148.53M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
FGEN's long-term liabilities ($266.75M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
FGEN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
FGEN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$2.7M
Investing
-$16.0k
Financing
-$88.0k
FGEN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
FGEN vs Biotech Stocks
Fibrogen Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.